News

COVID-19.info

Popularization of research advances on COVID-19

Website developed by 100pour100 MEDECINE

2021 - Page 28 of 29 - News Covid-19.info

The sensitivity of tests is secondary to the speed of results

Individuals infected by SARS-CoV-2 can transmit the virus whether they are pre-symptomatic (the period prior to the beginning of symptoms), symptomatic or asymptomatic. After becoming infected, an individual undergoes a period of incubation during which time the viral charge is too small to be detected. This is followed by a phase of exponential multiplication of […]

Read more...

Baricitinib: a drug that is twice as effective?

Severe cases of COVID-19 are linked to hyper-inflammation in association with a “cytokine storm”, bringing about lung function failure and acute respiratory syndrome. However other organs such as the liver (in 60% of severe cases), the vascular system, the brain or the kidneys can also be affected for reasons that we don’t yet fully understand. […]

Read more...

How does Paquinimod work?

Paquinimod is a specific inhibitor of S1001A8/A9 alarmins and significantly reduces numbers of the neutrophil sub-population (abnormal polynuclear neutrophils). This molecule seems to have the therapeutic potential to suppress an uncontrolled immune response associated with the pathology observed in severe forms of COVID-19. How does Paquinimod work? It must be remembered that innate immunity is […]

Read more...

Which proteins contribute to infection?

In the last 20 years, several coronaviruses have appeared. There was SARS-CoV-1 in 2002, MERS-CoV (Middle East Respiratory Syndrome) in 2012 and finally SARS-CoV-2, which appeared in 2019. This rapid evolution provides opportunities to discover common inhibitors, so that older therapies can remain effective in the future. In order to understand the degree of similarity […]

Read more...

How have vaccines been produced so quickly?

How has it been possible to develop a vaccine against COVID-19 in such a short period of time? This success is linked to the exceptional nature of the situation, of which 3 aspects might be underlined:  Unlike other epidemics, many countries have simultaneously faced economic catastrophe, and the millions spent on alleviating the situation have […]

Read more...

Has the number of COVID-19 cases in France been under-estimated?

The purpose of virus detection is to identify and isolate COVID-19 patients so as to limit transmission and control the outbreak. But positive cases have been largely under-estimated since many of them are asymptomatic or cause only slight symptoms, and so are not counted. At the beginning of the epidemic, because nothing like this had […]

Read more...

Are antibodies transmitted to the foetus?

Certain sectors of the population are more at risk during the COVID-19 epidemic. This is especially true of pregnant women, amongst whom there are more severe cases than in other people of the same age. The foetus protects itself from pathogens through the transfer of maternal antibodies (IgG) via the placenta. This transfer of antibodies […]

Read more...

The two faces of the Spike

SARS-CoV-2 belongs to the family of Beta-coronaviruses. Out of the 7 viruses from this family that infect humans, two have already been responsible for epidemics and are relatively close to SARS-CoV-2 (SARS-CoV-1 and MERS-CoV), while the others are seasonal viruses causing respiratory infections. SARS-CoV-2 is an enveloped virus, with a single-stranded RNA genome (one of […]

Read more...

What about the risk of secondary infections?

It has now been established that following SARS-CoV-2 infection, we efficiently generate antibodies against the virus. Some of these, the neutralizing antibodies, have the potential to block the binding of the virus to a target cell, but it has not yet been clearly established if they can give protection against new infection by the same […]

Read more...

Fighting the virus with the help of its receptor

One of the difficulties in the fight against SARS-CoV-2 is that virus mutations may enable it to avoid the action of antibodies produced after vaccination or administered via passive therapies. Mutations of the spike (S) protein may enable the virus to avoid the effects of anti-S neutralizing antibodies that usually block infection. Specifically, the spike’s […]

Read more...
error: Content is protected !!